Merck announces positive OS data for 1L pembrolizumab in NSCLC

The addition of Merck/MSD’s pembrolizumab (Keytruda) to platinum and pemetrexed chemotherapy for first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) significantly improves overall survival (OS), with patients treated with the triplet therapy having approximately half the risk of death or disease-free survival events compared with platinum plus pemetrexed doublet therapy.

Read more